CERo color.jpg
CERo Therapeutics Holdings, Inc. Highlights Progress
06 févr. 2025 08h15 HE | CERo Therapeutics Holdings, Inc.
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics...
CytoMed logo.png
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
06 févr. 2025 07h20 HE | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board...
Cellectis Logo.png
Monthly information on share capital and company voting rights
04 févr. 2025 16h30 HE | Cellectis Inc.
PARIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595    DateTotal number of sharesin the capitalTotal number of voting...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Announces $55.6 Million Private Placement
27 déc. 2024 09h00 HE | Vor Biopharma
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
CytoMed logo.png
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
20 nov. 2024 07h00 HE | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...
WUGEN-Logo-White-Background-FIN.jpg
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma
12 nov. 2024 07h00 HE | Wugen
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
Vaccinex logo
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
07 nov. 2024 08h30 HE | Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Cellectis Logo.png
Monthly information on share capital and company voting rights
06 nov. 2024 16h38 HE | Cellectis Inc.
PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Logo.png
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
05 nov. 2024 16h30 HE | Cellectis Inc.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Logo.png
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30 oct. 2024 16h30 HE | Cellectis Inc.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...